Motilal Oswal Alternates on Tuesday announced a Rs 450-crore investment in Mega Fine Pharma for a majority stake. The Sanghvi family, the promoters of the company, have also invested in a bid to increase their stake in the export-focused integrated API company, as per an official statement.